hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06353204 id: 3325 briefTitle: Effectiveness of the Justice Diversion Halt-intervention overallStatus: RECRUITING date: 2024-02-01 date: 2027-07 date: 2027-07 date: 2024-04-09 date: 2024-04-09 name: Wetenschappelijk Onderzoek en Datacentrum class: OTHER_GOV name: Utrecht University name: Leiden University briefSummary: In the current study the effectiveness of the Dutch diversion measure Halt is investigated using a randomized controlled trial. Because of the thorough scientific substantiation of the intervention theory, it is hypothesized that receiving the Halt-intervention will lead to less recidivism in comparison to receiving no intervention. conditions: Criminal Recidivism conditions: Delinquency conditions: Antisocial Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A comparison between two groups will be made. One half of the participants will be randomly assigned to a group that receives the Halt-intervention, while the other group receives no Halt-intervention. primaryPurpose: TREATMENT masking: NONE count: 1300 type: ESTIMATED name: Halt-intervention measure: Criminal Recidivism based on self-report measure: Criminal Recidivism based on official police records measure: Criminal Recidivism based on official judiciary records measure: Truancy based on self-report measure: Conventional beliefs measure: Minimizing/mislabeling measure: Social skills measure: Taking responsibility for the consequences of behavior measure: Correct wrongdoing measure: Support from social network measure: Experienced legitimacy measure: Experienced treatment measure: Receiving adequate information measure: The right to be informed measure: Experienced voluntariness measure: Access to legal assistance measure: Knowledge of not obtaining a criminal record measure: Experienced stigmatisation measure: Experienced re-integration measure: Mental health problems during the last six months measure: Experienced problems measure: Delinquent friends measure: Parental involvement measure: Demographical characteristics measure: Halt-intervention program integrity measure: Characteristics Halt-employee measure: Perceived relationship with Halt-employee measure: Educational attainment measure: Type of criminal offense measure: Characteristics of referral to Halt-intervention measure: Types of modules used during the Halt-intervention measure: Parts of the Halt-intervention carries out as group or solo intervention sex: ALL minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: WODC status: RECRUITING city: The Hague state: Zuid-Holland zip: 2500EH country: Netherlands name: Benthe J van Delft, MSc role: CONTACT email: b.j.van.delft@wodc.nl lat: 52.07667 lon: 4.29861 hasResults: False
nctId: NCT06353191 id: 19-002566 id: NCI-2024-00943 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 19-002566 type: OTHER domain: Mayo Clinic in Florida id: P30CA015083 type: NIH link: https://reporter.nih.gov/quickSearch/P30CA015083 id: R01HL169268 type: NIH link: https://reporter.nih.gov/quickSearch/R01HL169268 id: R56HL160643 type: NIH link: https://reporter.nih.gov/quickSearch/R56HL160643 briefTitle: Biomarkers to Predict Cancer Therapy-related Cardiotoxicity overallStatus: RECRUITING date: 2019-05-03 date: 2026-06-01 date: 2026-06-01 date: 2024-04-08 date: 2024-04-08 name: Mayo Clinic class: OTHER name: National Cancer Institute (NCI) name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy. conditions: Hematopoietic and Lymphatic System Neoplasm conditions: Malignant Solid Neoplasm studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Non-Interventional Study measure: Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona status: RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Myrah Manuel role: CONTACT phone: 480-574-3157 email: Manuel.Myrah@mayo.edu name: Lida A. Mina, MD role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: Mayo Clinic in Florida status: RECRUITING city: Jacksonville state: Florida zip: 32224-9980 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Pamela Williamson role: CONTACT phone: 904-953-4694 email: Williamson.Pamela@mayo.edu name: Nadine Norton, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 facility: Mayo Clinic in Rochester status: SUSPENDED city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06353178 id: 20240314 briefTitle: Building Empowerment and Coping Outcomes for caNcer Patients, Survivors and Their Caregivers acronym: BEACON overallStatus: RECRUITING date: 2024-04-08 date: 2025-02-01 date: 2025-04-01 date: 2024-04-08 date: 2024-04-08 name: Color Health, Inc. class: INDUSTRY briefSummary: Cancer has a psychological, emotional and social impact beyond a patient's physical health. This study examines three new online peer mental-wellness support program for cancer patients, survivors or their caregivers. Each program teaches evidence-based skills, in the context of that groups lived experience, to manage the emotional impact of cancer. This study examines the impact of that program. conditions: Cancer conditions: Caregiving Stress conditions: Caregiver Burnout conditions: Survivorship studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized to waitlist or intervention group. Those in intervention group will receive the peer program; those on the waitlist will receive it after being on the waitlist for 3 months. primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: Participants will be notified of a waitlist assignment upon enrolling. Those on the waitlist will receive the intervention after 3 months. count: 120 type: ESTIMATED name: Cancer Connect Program measure: Quality of Life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Color Health status: RECRUITING city: Burlingame state: California zip: 94010 country: United States lat: 37.5841 lon: -122.36608 hasResults: False
nctId: NCT06353165 id: CRO-2022-12-BAC-SNF-THA-YPZ briefTitle: Anti-bacterial Clinical Study on Teeth, Tongue, Cheek, Gum, and Saliva overallStatus: COMPLETED date: 2023-03-08 date: 2023-04-12 date: 2023-04-12 date: 2024-04-08 date: 2024-04-15 name: Colgate Palmolive class: INDUSTRY briefSummary: This 4-week clinical study was designed to examine the antibacterial efficacy of brushing with a 0.454% stannous fluoride toothpaste with potassium nitrate and pyrophosphate compared to a toothpaste containing 0.76% MFP (marketed as Colgate Cavity Protection Toothpaste) in different regions of the mouth (dental plaque, tongue, cheek, gum surface and in saliva) 12 hours post-brushing (overnight) after 2 and 4 weeks of product use. conditions: Plaque, Dental studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: blinded primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ACTUAL name: Stannous fluoride toothpaste name: Colgate Dental Cream measure: Whole mouth scores of dental plaque measure: Measurement of total bacterial counts on tongue measure: Measurement of total bacterial counts on cheek measure: Measurement of gingivitis measure: Measurement of total bacterial counts in saliva sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: M U International Oral Science Research, Ltd. city: Bangkok state: Krung Thep Maha Nakhon zip: 10250 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06353152 id: GC506-507 briefTitle: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma overallStatus: RECRUITING date: 2023-11-17 date: 2025-11-16 date: 2025-11-16 date: 2024-04-08 date: 2024-04-08 name: Peking University class: OTHER name: Gracell Biopharmaceuticals, Inc. briefSummary: A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma. conditions: Gastric Adenocarcinoma conditions: Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection measure: Occurrence of Dose limiting toxicity. measure: Incidence of treatment-emergent AEs, AESIs, and SAEs. measure: Disease control rate (DCR) measure: Objective response rate (ORR) measure: Duration of disease control (DDC) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Proliferation and persistence of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell measure: Incidence of anti-CAR-T cell antibody in peripheral blood after infusion. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing state: Beijing zip: 100142 country: China name: Shen Lin, Professor role: CONTACT phone: 010-88196561 email: doctorshenlin@sina.cn name: Shen Lin, professor role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06353139 id: 90591 briefTitle: The Efficacy of Modified Olfactory Training for Patients With Olfactory Dysfunction overallStatus: RECRUITING date: 2023-07-01 date: 2024-12-31 date: 2024-12-31 date: 2024-04-08 date: 2024-04-08 name: Peking University Third Hospital class: OTHER briefSummary: The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are:
Is it possible that the device can treat olfactory disorders in adults? Compared to the conventional device, how efficient is the modified olfactory training device for treating patients with olfactory disfunction? conditions: Olfactory Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 72 type: ESTIMATED name: Modified olfactory training device measure: Clinically significant olfactory improvement sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dawei Wu status: RECRUITING city: Beijing state: Beijing zip: 100191 country: China name: Dawei Wu, MD, PhD role: CONTACT phone: 13522503401 email: davidwuorl@163.com role: CONTACT phoneExt: Wu email: davidwuorl@163.com name: Dawei Wu, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06353126 id: DTACESALT briefTitle: DEB-TACE Prior to Liver Transplantation in the Treatment of HCC overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-07-01 date: 2027-07-01 date: 2024-04-08 date: 2024-04-08 name: RenJi Hospital class: OTHER name: Boston Scientific Corporation briefSummary: The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to SALT (Sequential Adult Left Lateral Liver Transplantation) can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for SALT receive DEB-TACE 2 weeks prior to the surgery.
The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS)；2) Pathological response rate (Pathological Response); 3) Proportion of patients completing SALT; 4) Adverse events related to DEB-TACE. conditions: Liver Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: DEB-TACE measure: Recurrence-free survival (RFS) measure: Overall survival (OS) measure: Pathological response rate (Pathological Response) measure: Proportion of patients completing SALT measure: Adverse events related to DEB-TACE sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353113 id: HS-2023-0254 briefTitle: Feasibility of a Prenatal Yoga Mobile App in African American Pregnant Women overallStatus: RECRUITING date: 2024-04 date: 2024-07 date: 2024-09 date: 2024-04-08 date: 2024-04-08 name: San Diego State University class: OTHER briefSummary: The goal of this research is to test if a prenatal yoga app can improve well-being in African American/Black (AA) pregnant women. The main questions it aims to answer are:
This project aims to advance public health by contributing to a broader understanding of how prenatal yoga can support the health and well-being of AA pregnant women and promote optimal maternal and child health outcomes. conditions: Pregnancy Related conditions: Mental Health Issue conditions: Discrimination, Racial conditions: Stress conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 50 type: ESTIMATED name: Down Dog Prenatal Yoga App measure: Acceptability of the intervention measure: Demand of the intervention measure: Retention measure: Ease of recruitment measure: Discrimination measure: Perceived stress measure: Perinatal Depression measure: Self-awareness measure: Mindfulness measure: Subjective physical activity measure: Objective physical activity (steps) measure: Objective physical activity (intensity) measure: Cardiac health (heart rate) measure: Cardiac health (heart rate variability) measure: Cultural adaptations measure: Birth outcomes (gestational age) measure: Birth outcomes (type of delivery) measure: Birth outcomes (intervention used for delivery) measure: Birth outcomes (birth weight) measure: Birth outcomes (maternal weight) measure: Birth outcomes (pregnancy-related disorders) sex: FEMALE minimumAge: 18 Years maximumAge: 46 Years stdAges: ADULT facility: San Diego State University status: RECRUITING city: San Diego state: California zip: 92182 country: United States name: Jeni Green, PhD role: CONTACT lat: 32.71533 lon: -117.15726 hasResults: False
nctId: NCT06353100 id: 230602006 briefTitle: Chronic Pain in the General Population of Chile acronym: RDC overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-01 date: 2024-12-30 date: 2024-12-30 date: 2024-04-08 date: 2024-04-08 name: Pontificia Universidad Catolica de Chile class: OTHER name: Chilean Safety Association (ACHS) briefSummary: The present study seeks to follow up the cohort of adults representative of Chile's urban population whose levels of chronic pain were evaluated in March 2023 (baseline) as part of the Mental Health Thermometer (MHT) study. The study consists of a 12 month follow-up telephone interview to assess parameters of chronic pain (CP) and subtypes, mental and physical health, lifestyle and adversity and work characteristics.
4. Describe the use of management strategies in those who suffer from CP. conditions: Chronic Pain conditions: Migraine Disability conditions: Neuropathic Pain conditions: Fibromyalgia conditions: Depression, Anxiety conditions: Self Harm conditions: Insomnia conditions: Loneliness studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2365 type: ACTUAL measure: Chronic pain (past 3 months) measure: Depression (2 weeks) measure: Anxiety (2 weeks) measure: Migraine Disability measure: Neuropathic Pain measure: Fibromyalgia measure: Self harm (2 weeks) measure: Insomnia (2 weeks) measure: Loneliness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pontificia Universidad Catolica de Chile city: Santiago state: RM zip: 7550139 country: Chile lat: -33.45694 lon: -70.64827 hasResults: False
nctId: NCT06353087 id: B7451114 briefTitle: Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) acronym: ATTRACT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-11-15 date: 2025-11-15 date: 2024-04-08 date: 2024-04-08 name: Pfizer class: INDUSTRY briefSummary: This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics. conditions: Dermatitis, Atopic conditions: Dermatitis conditions: Eczema conditions: Skin Diseases conditions: Immune System Diseases conditions: Janus Kinase Inhibitors studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Percentage of Participants Achieving >= 75% Improvement From Baseline in Eczema Area and Severity Index (EASI-75) Response at Week 2, 12, 52 measure: Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 2, 12, 52 measure: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 2, 12, 52 measure: Duration of Abrocitinib Treatment: All Participants measure: Demographic and baseline characteristics measure: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 12, 16, 24, and 52 measure: Change From Baseline in Investigator's Global Assessment (IGA) at Weeks 2, 4, 12, 16, 24, and 52 measure: Change From Baseline in Percentage Body Surface Area at Week 2, 4, 12, 16, 24, and 52 measure: Change From Baseline in Patient-Oriented Eczema Measure (POEM) at Week 2, 4, 12, and 52 measure: Change from baseline of Atopic Dermatitis Control Tool (ADCT) score at Week 2, 4, 12, and 52 measure: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score to Week 2, 4, 12, and 52 measure: Change From Baseline in Patient Global Assessment (PtGA) measure: Percentage Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 2, 4, 12, 16, 24, and 52 measure: Percentage of Participants Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Week 2, 4, 12, 16, 24, and 52 measure: Percentage of Participants Achieving 0 or 1 in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Week 2, 4, 12, 16, 24, and 52 sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353074 id: 1335cemre. briefTitle: Uterine Preservation With Acar's Atony Suture for Postpartum Uterine Hemorrhage overallStatus: COMPLETED date: 2021-01-01 date: 2023-11-30 date: 2023-11-30 date: 2024-04-08 date: 2024-04-08 name: Necmettin Erbakan University class: OTHER briefSummary: This study is aimed to show effectiveness of a new suture technique to stop postpartum uterine bleeding due to uterine atony. conditions: Uterine Atony With Hemorrhage conditions: Postpartum Hemorrhage studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 16 type: ACTUAL measure: Postpartum hysterectomy and/or intensive care unit need ratio sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Cemre Alan city: Konya country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06353061 id: LACC-MET briefTitle: Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-08-01 date: 2026-02-01 date: 2024-04-08 date: 2024-04-08 name: Peking Union Medical College Hospital class: OTHER briefSummary: This is a prospective, single-center, phase II, randomized, window-of-opportunity trial initiated by researchers. The research hypothesis is that metformin can improve the level of hypoxia in locally advanced cervical cancer and further improve progression-free survival. The study aims to compare the improvement of tumor hypoxia with synchronous chemoradiotherapy with or without metformin, using CA-IX PET/CT and radiation positioning spectral CT to evaluate tumor hypoxia, screening hypoxic patients for inclusion in the study, and comparing the effects of synchronous chemoradiotherapy with or without metformin on the degree of hypoxia and progression-free survival in the two groups of patients. conditions: Cervical Cancer conditions: Radiotherapy conditions: Metformin conditions: Hypoxia conditions: PET/CT studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 51 type: ESTIMATED name: Metformin name: Radiotherapy name: Chemotherapy name: PET/CT measure: The degree to which metformin improves the hypoxic index measured by CAIX PET measure: Progression-free survival（PFS） measure: Changes in tumor volume during treatment measure: Hematologic and gastrointestinal toxicities assessed by CTCAE v5.0 measure: Quality of life assessed by QLQ-C30 sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353048 id: Soh-Med-24-02-04MS briefTitle: Short Term Radiological and Clinical Outcomes of Fixation of Schatzker II Tibial Plateau Fractures by Screws Only Versus Plate and Screws , Comparative Study overallStatus: RECRUITING date: 2024-02-10 date: 2025-02-15 date: 2025-02-15 date: 2024-04-08 date: 2024-04-08 name: Sohag University class: OTHER name: sohag university hospital briefSummary: Tibial plateau fractures are complex injuries produced by high- or low-energy trauma. They principally affect young adults or the 'third age' population ,the tibial plateau is a major weight-bearing surface within the largest and most kinematically complex joint in the human body. Fractures occur as a result of a combination of an axial loading force and a coronal plane (varus/valgus) moment leading to articular shear and depression and mechanical axis malalignment,So Limb alignment and articular surface restoration, allowing early knee motion, are the main goals of surgical treatment.
Soft-tissue damage in fractures around the knee is of critical importance. The oedema and inflammation associated with the trauma can easily lead to local venous compromise, dermal hypoxia, and additional soft-tissue injury. This commonly leads to blistering of the skin and in some cases dermal and even muscle necrosis. Blood-filled blisters should be expected to be associated with a worse outcome than clear fluid-filled ones. Management in the early stages of treatment should focus on preventing further soft-tissue injury while waiting to repair the fracture.
Traditionally, initial radiograph diagnosis should include anteroposterior (AP), lateral and oblique views. But single radiographs do not allow an exact fragment identification and the initial fracture classification can change in 5% to 24% (mean 12%) of cases and treatment can change in up to 26% of cases after CT scan imaging . These findings and the wider availability of CT scanning have made the oblique views less important in the diagnosis. Intra- and peri-articular soft-tissue structures can be affected even in less complex fracture patterns and some X-ray or CT scan data can also suggest the existence of a lateral or medial meniscal tear. Articular depression \> 6 mm and/or articular widening \> 5 mm are associated with the existence of lateral meniscus, lateral collateral ligament (LCL) or posterior cruciate ligament injuries .